patients without any clinical consequences. There were no other safety concerns.

Conclusion No significant safety concerns were identified for the adjunctive use of PP-007in patients undergoing MT (ClinicalTrials.gov NCT04677777).

Disclosures I. Linfante: 2; C; Penumbra, Stryker, Q'Appel, Cerenovus. 3; C; Penumbra, Stryker, Q'Appel, Cerenovus. 4; C; Prolong Pharmaceuticals, InNeuroCo,Three Rivers, InNeuroFine, Deinde. **W. Clark:** None. **D. Houssen:** None. **R. Hanel:** None. **R. Reshi:** None. **G. Dabus:** 4; C; three rivers, InNeuroCo, synchron. **R. Jubin:** 5; C; Prolong Pharmaceuticals. **T. Nguyen:** None. **J. Grotta:** None. **R. Wicks:** None. **M. Pervez:** None. **M. Cipolla:** None. **D. Liebeskind:** None. **R. Nogueira:** None.

LB-006 TREATMENT OF MIDDLE CEREBRAL ARTERY BIFURCATION ANEURYSMS WITH NEW GENERATION LOW PROFILE FLOW DIVERTERS COMBINED WITH PROLONGED DUAL ANTI-PLATELET THERAPY; COVERED BRANCH ANALYSIS

I Lylyk, P Lylyk*, J Lundquist, C Bleise, E Scrivano, N Perez, R Nella Castro, P Lylyk. *Endovascular Neurosurgery, ENERI – Clínica la Sagrada Familia, Ciudad autónoma de Buenos Aires, ARGENTINA*

10.1136/jnis-2023-SNIS.380

Introduction In recent years, there has been a growing interest in using flow diverters (FD) to treat MCA aneurysms.

Aim of study In this study, we investigated the safety and effectiveness of new generation low profile flow diverters to treat middle cerebral artery (MCA) bifurcation aneurysms among all patients treated for intracranial aneurysms at our center.

Methods This was a single center, single-arm retrospective study of prospectively collected data of patients treated with p48 HPC, p64 HPC, Silk Vista Baby and PED Shield Vantage at our high-volume center between March 2018–March 2023. The primary efficacy endpoint was complete occlusion as measured by a class 1 Raymond-Roy score at 1-year and 2-year follow-up. The primary safety endpoint was major morbidity and neurological mortality up to 2 years following intervention.

Results A total of 75 patients (mean age 57.1±2.7 years; 83.9% female) with 75 saccular MCA aneurysms (mean size 4.6±3.2 mm) were treated with a low-profile FD. A total of 83 devices were deployed, with 94.6% (71/75) of aneurysms requiring only one device. Intraprocedural technical complications occurred in 5.3% (4/75), 2 shortening of the device requiring an additional FD, 1 in-stent thrombosis, 1 subarachnoid hemorrhage post-procedure. Follow-up angiography was available for 73.3% (55/75) of the patients at a mean time of 12.4 months. Complete occlusion was demonstrated for 56.0% of aneurysms at 6 months, 63.2% at 12 months and 81,9% at 24 months. The overall rates of major morbidity and neurological mortality after 2 years were 2.7% (2/75) and 0% respectively. 5.3% of jailed branches presented an asymptomatic narrowing, 5.3% an asymptomatic occlusion and 1.3% presented a symptomatic occlusion. Dual antiplatelet therapy was maintained with prasugrel 10mg/day and AAS 100mg/day 1 year following FD implantation then continued with AAS 100mg/day.

Conclusion Low profile new generation flow diverters combined with prolonged DAPT therapy with prasugrel demonstrated high rates of complete long-term occlusion, as well as low rates of mortality and morbidity consistent with fewer symptomatic jailed artery occlusions.

Disclosures I. Lylyk: None. **P. Lylyk:** None. **J. Lundquist:** None. **C. Bleise:** None. **E. Scrivano:** None. **N. Perez:** None. **R. Nella Castro:** None. **P. Lylyk:** None.

LB-007 SELECTIVE BRAIN COOLING IS POSSIBLE VIA CSF EXCHANGE WITH DOUBLE LUMEN EVD-PROOF OF CONCEPT IN PORCINE STROKE MODEL

[1]B Rezai Jahromi*, [2]N Järveläinen, [3]J Kauhanen, [1]V Zamotin, [4]N Brandmeir, [1]M Niemelä, [5]S Ylä-Herttuala. *[1]Department of Neurosurgery, Helsinki University Hospital, Helsinki, FINLAND; [2]Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, FINLAND; [3]Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University Of Eastern Finland, Kuopio, FINLAND; [4]Department of Neurosurgery, University Of West Virginia, West Virginia, WV; [5]A.I. Virtanen Institute for Molecular Sciences, Faculty of Health Sciences,, Kuopio, FINLAND*

10.1136/jnis-2023-SNIS.381

Introduction Hypothermia is seen as neuroprotective after brain insult (BI). In acute phase after BI it affects brain metabolism by decreasing oxygen and glucose consumption. Hypothermia affects apoptosis and inflammatory mediators. In the later stage of BI, enzyme activation stimulates protein and lipid breakdown, which can be slowed and decreased with hypothermia. In the latest stage of BI hypothermia has shown positive affect in angiogenesis, neurogenesis, synaptogenesis. Hypothermia also reduces vasogenic oedema and blood brain barrier dysfunction. Despite hypothermia´s neuroprotective effect randomized control trials have demonstrated its benefits only limited scenarios - mainly in global ischemia (post-cardiac infarction and ischemia of new-born). Majority of complications related to hypothermia has been due to systemic hypothermia and selective brain cooling has never been demonstrated in large mammals without changes in core temperature of subject.

Objective We hypothesized that by actively exchanging cerebrospinal fluid (CSF) to cooled NaCl and ringer acetate solution we can reduce selectively brain temperature without changes in core temperature of porcine body.

Methods We inserted double lumen external ventricular drainage (EVD) into the lateral ventricle of four porcines. We added spinal drainage to accelerate CSF exchange to cooled NaCl (one porcine)/ringer acetate (three porcine) solutions. Brain parenchymal temperature was measured from the contralateral brain hemisphere and the ipsilateral brain hemisphere. We exchanged CSF to cooled solution in 4 porcine with rates of 180ml-720ml/h. Two of porcine were induced global stroke via endovascular method by closing brains main arteries for 20 min.

Results Contralateral brain hemisphere temperature dropped by 2.2-3.1C from baseline while core temperature changed only by 0.5C. Ipsilateral temperature cooled by 4.5-7.5C from baseline to 29.9-33.8C, while core temperature was on average 37.7C. Total time needed to achieve selective cooling was highly dependent on CSF rate from 10min to 1.5h. One porcine started to have arrhythmias when brain temperature approached 30.8C, in this case CSF exchange was done with NaCl solution, other 3 porcine did not have similar adverse events with ringer acetate. In two stroke induced porcine selective brain cooling was achieved despite 140 mmHg median arterial pressure after stroke.